656 related articles for article (PubMed ID: 8760286)
1. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway.
Song JS; Haleem-Smith H; Arudchandran R; Gomez J; Scott PM; Mill JF; Tan TH; Rivera J
J Immunol; 1999 Jul; 163(2):802-10. PubMed ID: 10395673
[TBL] [Abstract][Full Text] [Related]
3. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
4. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth.
Murphy GA; Solski PA; Jillian SA; Pérez de la Ossa P; D'Eustachio P; Der CJ; Rush MG
Oncogene; 1999 Jul; 18(26):3831-45. PubMed ID: 10445846
[TBL] [Abstract][Full Text] [Related]
5. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
7. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway.
Salojin KV; Zhang J; Delovitch TL
J Immunol; 1999 Jul; 163(2):844-53. PubMed ID: 10395678
[TBL] [Abstract][Full Text] [Related]
8. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB.
Murga C; Zohar M; Teramoto H; Gutkind JS
Oncogene; 2002 Jan; 21(2):207-16. PubMed ID: 11803464
[TBL] [Abstract][Full Text] [Related]
9. A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation.
Urich M; Senften M; Shaw PE; Ballmer-Hofer K
Oncogene; 1997 Mar; 14(10):1235-41. PubMed ID: 9121774
[TBL] [Abstract][Full Text] [Related]
10. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
11. Cooperative transformation of NIH3T3 cells by G alpha12 and Rac1.
Tolkacheva T; Feuer B; Lorenzi MV; Saez R; Chan AM
Oncogene; 1997 Aug; 15(6):727-35. PubMed ID: 9264413
[TBL] [Abstract][Full Text] [Related]
12. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades.
O'Hagan RC; Tozer RG; Symons M; McCormick F; Hassell JA
Oncogene; 1996 Sep; 13(6):1323-33. PubMed ID: 8808707
[TBL] [Abstract][Full Text] [Related]
13. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product.
Crespo P; Schuebel KE; Ostrom AA; Gutkind JS; Bustelo XR
Nature; 1997 Jan; 385(6612):169-72. PubMed ID: 8990121
[TBL] [Abstract][Full Text] [Related]
14. Vav: function and regulation in hematopoietic cell signaling.
Bonnefoy-Bérard N; Munshi A; Yron I; Wu S; Collins TL; Deckert M; Shalom-Barak T; Giampa L; Herbert E; Hernandez J; Meller N; Couture C; Altman A
Stem Cells; 1996 May; 14(3):250-68. PubMed ID: 8724692
[TBL] [Abstract][Full Text] [Related]
15. Stress-activated protein kinases are negatively regulated by cell density.
Lallemand D; Ham J; Garbay S; Bakiri L; Traincard F; Jeannequin O; Pfarr CM; Yaniv M
EMBO J; 1998 Oct; 17(19):5615-26. PubMed ID: 9755162
[TBL] [Abstract][Full Text] [Related]
16. The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo.
Bellanger JM; Lazaro JB; Diriong S; Fernandez A; Lamb N; Debant A
Oncogene; 1998 Jan; 16(2):147-52. PubMed ID: 9464532
[TBL] [Abstract][Full Text] [Related]
17. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase.
O'Hagan RC; Hassell JA
Oncogene; 1998 Jan; 16(3):301-10. PubMed ID: 9467955
[TBL] [Abstract][Full Text] [Related]
18. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
19. Faciogenital dysplasia protein (FGD1) and Vav, two related proteins required for normal embryonic development, are upstream regulators of Rho GTPases.
Olson MF; Pasteris NG; Gorski JL; Hall A
Curr Biol; 1996 Dec; 6(12):1628-33. PubMed ID: 8994827
[TBL] [Abstract][Full Text] [Related]
20. Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42.
Lorenzi MV; Castagnino P; Chen Q; Hori Y; Miki T
Oncogene; 1999 Aug; 18(33):4742-55. PubMed ID: 10467422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
